Expression of cancer testis antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention? Journal Article
| Authors: | Adams, S.; Greeder, L.; Reich, E.; Shao, Y.; Fosina, D.; Hanson, N.; Tassello, J.; Singh, B.; Spagnoli, G. C.; Demaria, S.; Jungbluth, A. A. |
| Article Title: | Expression of cancer testis antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention? |
| Abstract: | Introduction: Novel breast cancer risk-reducing strategies for individuals with germline mutations of the BRCA1 and/or BRCA2 genes are urgently needed. Identification of antigenic targets that are expressed in early cancers, but absent in normal breast epithelium of these high-risk individuals, could provide the basis for the development of effective immunoprophylactic strategies. Cancer testis (CT) antigens are potential candidates because their expression is restricted to tumors, and accumulating data suggest that they play important roles in cellular proliferation, stem cell function, and carcinogenesis. The objective of this study was to examine the expression of CT antigens and their frequency in BRCA-associated breast cancers. Methods: Archived breast cancer tissues (n = 26) as well as morphologically normal breast tissues (n = 7) from women carrying deleterious BRCA 1 and/or 2 mutations were obtained for antigen expression analysis by immunohistochemistry. Expression of the following CT antigens was examined: MAGE-A1, MAGE-A3, MAGE-A4, MAGE-C1.CT7, NY-ESO-1, MAGE-C2/CT10, and GAGE. Results: CT antigens were expressed in 16/26 (61.5%, 95% CI 43-80%) of BRCA-associated cancers, including in situ tumors. Thirteen of twenty-six (50%) breast cancers expressed two or more CT antigens; three cancers expressed all seven CT antigens. MAGE-A was expressed in 13/26 (50%) of cancers, NY-ESO-1 was expressed in 10/26 (38%) of tumors. In contrast, none of the CT antigens were expressed in adjacent or contralateral normal breast epithelium (P = 0.003). Conclusions: We report a high CT antigen expression rate in BRCA-associated breast cancer as well as the lack of expression of these antigens in benign breast tissue of carriers, identifying CT antigens as potential vaccine targets for breast cancer prevention in these high-risk individuals. © 2011 Springer-Verlag. |
| Keywords: | immunohistochemistry; adult; clinical article; controlled study; human tissue; unclassified drug; gene mutation; human cell; gene deletion; antigen expression; cancer immunotherapy; cancer prevention; breast cancer; mastectomy; brca1 protein; tumor antigen; cancer testis antigen; melanoma antigen 1; ny eso 1 antigen; breast epithelium; melanoma antigen; melanoma antigen a3; melanoma antigen a4; melanoma antigen c1; intraductal carcinoma; vaccine; gage antigen; ny-eso-1; prevention; mage-a; brca1/2; melanoma antigen c2 |
| Journal Title: | Cancer Immunology, Immunotherapy |
| Volume: | 60 |
| Issue: | 7 |
| ISSN: | 0340-7004 |
| Publisher: | Springer |
| Date Published: | 2011-07-01 |
| Start Page: | 999 |
| End Page: | 1007 |
| Language: | English |
| DOI: | 10.1007/s00262-011-1005-7 |
| PROVIDER: | scopus |
| PUBMED: | 21465317 |
| PMCID: | PMC3678385 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 17 August 2011" - "CODEN: CIIMD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work